OJPed  Vol.5 No.1 , March 2015
Syrup versus Drops of Iron III Hydroxide Polymaltose in the Treatment of Iron Deficiency Anemia of Infancy
Abstract: Background: Iron deficiency anemia in infants is the most common micronutrient deficiency worldwide. The main cause is low iron intake in the presence of accelerated physiologic growth rate. Objective: The current study aimed at prospectively comparing the efficacy of iron III hydroxide polymaltose syrup (IPS) versus iron III hydroxide polymaltose drops (IPD) in treating iron deficiency among infants attending the hematology outpatient clinic. Our hypothesis was that IPS would be less effective possibly related to the difficulty of giving the medication. Methods: Participants diagnosed with iron deficiency anemia between 11-24 months were randomly assigned to receive either IPS or IPD for 3 months. The main outcome parameter was hemoglobin blood level, while the secondary outcome parameters were: 1) iron; 2) ferritin; 3) transferrin (i.e. total iron binding capacity); 4) mean corpuscular volume; and 5) red blood cell distribution width. Results: Out of the 104 recruited infants, 55 (52%) completed the study: 29 in the IPS group and26 inthe IPD group. There was no significant difference in the main outcome parameter at either 1 or 3 months of treatment: mean hemoglobin was 10.5 versus 10.7 g/dL within a 1 month treatment, P = 0.4; mean hemoglobin was 11.0 versus 11.1 g/dL within a 3 months of treatment, P = 0.59. Likewise, no significant differences were found with respect to the occurrence of side effects. Conclusion: Oral IPD and IPS are equally effective in treating iron deficiency anemia in infants aged 11 - 24 months.
Cite this paper: Yahav, A. , Kaplinsky, C. , Glatstein, M. , Shachter, Y. , Simmonds, A. , Shiff, Y. , Scolnik, D. , Sharon, N. (2015) Syrup versus Drops of Iron III Hydroxide Polymaltose in the Treatment of Iron Deficiency Anemia of Infancy. Open Journal of Pediatrics, 5, 34-38. doi: 10.4236/ojped.2015.51007.

[1]   Bopche, A.V., Dwiverdi, R., Mishra, R., et al. (2009) Ferrous Sulfate versus Iron Polymaltose Complex for Treatment of Iron Deficiency Anemia in Children. Indian Pediatrics, 46, 883-885.

[2]   DeMaeyer, E. and Adiels-Tegman, M. (1985) The Prevalence of Anaemia in the World. World Health Statistics Quarterly, 38, 302-316.

[3]   Meyerovitch, J., Sherf, M., Antebi, F., Barhoum-Noufi, M., Horev, Z., Jaber, L., Weiss, D. and Koren, A. (2006) The Incidence of Anemia in an Israeli Population: A Population Analysis for Anemia in 34,512 Israeli Infants Aged 9 to 18 Months. Pediatrics, 118, e1055-e1060.

[4]   Lozoff, B., De Andraca, I., Castillo, M., et al. (2003) Behavioral and Developmental Effects of Preventing Iron Deficiency Anemia in Healthy Full Term Infants. Pediatrics, 112, 846-854.

[5]   Jaber, L., Tamary, H., et al. (2010) Iron Polymatose versus Ferrous Gluconate in the Prevention of Iron Deficiency Anemia of Infancy. Journal of Pediatric Hematology/Oncology, 32, 585-588.

[6]   Wright, C.M., Kelly, J., Trail, A., Parkinson, K.N. and Summerfield, G. (2004) The Diagnosis of Borderline Iron Deficiency: Results of a Therapeutic Trial. Archives of Disease in Childhood, 89, 1028-1031.

[7]   Lozoff, B., Jimenez, E. and Wolf, A.W. (1991) Long Term Development Outcome of Infants with Iron Deficiency. The New England Journal of Medicine, 325, 687-694.

[8]   Pizarro, F., Yip, R., Dallman, P.R., et al. (1991) Iron Status with Different Infant Feeding Regimens: Relevance to Screening and Prevention of Deficiency. Journal of Pediatrics, 118, 687-692.

[9]   Glazer, Y. and Bilenko, N. (2010) Effect of Iron Deficiency and Iron Deficiency Anemia in the First Two Years of Life on Cognitive and Mental Development during Childhood. Harefuah, 149, 309-314, 335.

[10]   Mujica-Coopman, M.F., Borja, A., Pizarro, F. and Olivares, M. (2015) Effect of Daily Supplementation with Iron and Zinc on Iron Status of Childbearing Age Women. Biological Trace Element Research.

[11]   Devaki, P.B., Chandra, R.K. and Geisser, P. (2008) Effects of Oral Supplementation with Iron (III) Hydroxide Polymaltose Complex on the Hematological Profile of Adolescents with Varying Iron Status. Arzneimittel-Forschung, 58, 389-397.

[12]   Nestel, P. and Alnwick, D. (1996) Iron-Micronutrient Supplements for Young Children. Summary and Conclusions of a Consultation Held at UNICEF, Copenhagen, 19-20 August 1996.

[13]   Borbolla, J.R., Cicero, R.E., Dibildox, M.M., Sotres, D.R. and Gutierrez, R.G. (2000) IPC vs. Iron Sulphate in the Treatment of Iron Deficiency in Infants. Rev Mex Padiatr, 67, 63-67.

[14]   Jacobs, P. (1984) Oral Iron Therapy in Human Subjects: Comparative Absorption between Ferrous Salts and Iron Polymaltose. Journal of Medicine, 3, 387-377.

[15]   Ortiz, R., Toblli, J.E., Romero, J.D., Monterrosa, B., Frer, C., Macagno, E. and Breymann, C. (2011) Efficacy and Safety of Oral Iron (III) Polymaltose Complex versus Ferrous Sulfate in Pregnant Women with Iron-Deficiency Anemia: A Multicenter, Randomized, Controlled Study. Journal of Maternal-Fetal and Neonatal Medicine, 24, 1347-1352.

[16]   Geltman, P.L., Meyers, A.F., Mehta, S.D., Brugnara, C., Villon, I., Wu, Y.A. and Bauchner, H. (2004) Daily Multivitamins with Iron to Prevent Anemia in High-Risk Infants: A Randomized Clinical Trial. Pediatrics, 114, 86-93.

[17]   Walter, T., Dallman, P.R., Pizarro, F., et al. (1993) Effectiveness of Iron Fortified Infant Cereal in Prevention of Iron Deficiency Anemia. Pediatrics, 91, 976-982.